Research & Development
Alpha-1-Antitrypsin (AAT) Pipeline
Scientific Research
Omni Bio has licensed pending patents for anti-microbial technology based on scientific research conducted at the University of Colorado Denver, under the supervision of Dr. Leland Shapiro MD, FACP. The Company anticipates entering into two additional strategic research agreements with the University of Colorado ("CU") related to a viral license and recently executed license agreement related to graft rejection technology.
We plan to collaborate with companies that have the infrastructure, expertise and large scale marketing capability to properly handle late-stage clinical development and commercialization.
License Agreements with the University of Colorado
Omni Bio has entered into exclusive license agreements with CU that relate to the broad therapeutic potential of Alpha 1 Antitrypsin ("AAT") as follows:
- May 2006: U.S. Provisional Patent Applications related to AAT in the treatment of anthrax, tuberculosis and bacterial pneumonia.
- March 2008: Issued method of use patent for AAT in treating various forms of viral infection, including, HIV and influenza.
- November 2008: AAT for the treatment of cell rejection.
Recent Publications
- Alpha-1-Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood (2/05/09) The Journal of Leukocyte Biology, Gregory B. Pott, Edward D. Chan, Charles A. Dinarello, and Leland Shapiro
- Keeping Diabetes ATT Bay (Dec 08) Nature Biotechnology, Peter Hare
- A tolerant alternative to immunosuppression (11/06/08) Science-Business eXchange, Kai-Jye Lou
- Well-known Drug (AAT) Could Overcome Obstacles To Islet Transplantation, Study Suggests (10/30/08) Science Daily
- Curative and Beta cell regenerative effects of alpha 1-antitrypsin treatment in autoimmune diabeticNOD mice (10/13/08) PNAS, Maria Koulmanda, Manoj Bhasin, Lauren Hoffman, Zhigang Fan, Andi Qipo, Hang Shi, Susan Bonner-Weir, Prabhakar Putheti, Nicolas Degauque, Towia A. Libermann, Hugh Auchincloss Jr., Jeffrey S. Flier, and Terry B. Strom
- α1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice (10/13/08) PNAS, Eli C. Lewis, Mark Mizrahi, Michel Toledano, Nathaniel DeFelice, Joanne L. Wright, Andrew Churg, Leland Shapiro, and Charles A. Dinarello
- An association between Type 2 diabetes and Alpha-1-antitrypsin deficiency (Jan 08) Diabetic Medicine, C. S. Sandström, B. Ohlsson, O. Melander, U. Westin, R. Mahadeva and S. Janciauskiene
- Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages (1/01/07) Scandinavian Journal of Infectious Diseases, EDWARD D. CHAN, ALEKSANDRA M. KAMINSKA1, WENDY GILL, KATHRYN CHMURA, NICOLE E. FELDMAN, XIYUAN BAI, CORINNE M. FLOYD, KAYTE E. FULTON, GWEN A. HUITT, MATTHEW J. STRAND, MICHAEL D. ISEMAN & LELAND SHAPIRO
- Saving islets from allograft rejection (9/06/05) PNAS, Terry B. Strom
- α1-Antitrypsin monotherapy prolongs islet allograft survival in mice (8/23/05) PNAS, Eli C. Lewis, Leland Shapiro, Owen J. Bowers, and Charles A. Dinarello
- Improving graft survival in islet transplantation (8/23/05) PNAS, EZ
- Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1 (1/15/01) FASEBJ, LELAND SHAPIRO, GREGORY B. POTT, AND ANNEMARIE H. RALSTON
